News
Imugene reports positive outcomes in novel virus trial against advanced cancers
Clinical stage immuno-oncology company Imugene (ASX: IMU) has obtained positive initial results from a clinical trial investigating its potential treatment of tumours with a unique cancer-killing virus. The phase 1 MAST (metastatic advanced solid tum
By: knowledia
- Jan 17 2024
- 0
- 0 Views
Clinical stage immuno-oncology company Imugene (ASX: IMU) has obtained positive initial results from a clinical trial investigating its potential treatment of tumours with a unique cancer-killing virus. The phase 1 MAST (metastatic advanced solid tumours) trial is currently evaluating the safety and efficacy of the novel cancer-killing virus CF33-hNIS (VAXINIA). The multi-centre phase 1 MAST […] The post Imugene reports positive outcomes in novel virus trial against advanced cancers appeared first on Small Caps.
Related
Share this page
Guest Posts by Easy Branches
